Vanguard Group Inc. decreased its holdings in Bruker Co. (NASDAQ:BRKR - Free Report) by 0.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 10,650,853 shares of the medical research company's stock after selling 47,322 shares during the quarter. Vanguard Group Inc. owned 7.03% of Bruker worth $624,353,000 at the end of the most recent reporting period.
Other institutional investors have also recently made changes to their positions in the company. Wealth Enhancement Advisory Services LLC boosted its position in Bruker by 1.4% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 13,287 shares of the medical research company's stock valued at $779,000 after buying an additional 177 shares during the period. Arizona State Retirement System boosted its holdings in Bruker by 0.7% in the fourth quarter. Arizona State Retirement System now owns 30,725 shares of the medical research company's stock valued at $1,801,000 after purchasing an additional 222 shares during the period. CIBC Asset Management Inc boosted its holdings in Bruker by 5.6% in the fourth quarter. CIBC Asset Management Inc now owns 4,233 shares of the medical research company's stock valued at $248,000 after purchasing an additional 223 shares during the period. UMB Bank n.a. grew its stake in Bruker by 37.5% during the 4th quarter. UMB Bank n.a. now owns 909 shares of the medical research company's stock worth $53,000 after purchasing an additional 248 shares in the last quarter. Finally, Blue Trust Inc. increased its holdings in Bruker by 13.5% during the 4th quarter. Blue Trust Inc. now owns 2,164 shares of the medical research company's stock worth $127,000 after purchasing an additional 257 shares during the period. Institutional investors and hedge funds own 79.52% of the company's stock.
Bruker Stock Performance
NASDAQ:BRKR traded down $1.20 during mid-day trading on Friday, reaching $36.46. 4,101,408 shares of the stock were exchanged, compared to its average volume of 1,398,669. The company has a quick ratio of 0.77, a current ratio of 1.60 and a debt-to-equity ratio of 1.15. Bruker Co. has a 1 year low of $34.13 and a 1 year high of $91.47. The company has a 50 day simple moving average of $48.64 and a 200-day simple moving average of $56.13. The stock has a market capitalization of $5.53 billion, a P/E ratio of 47.97, a P/E/G ratio of 2.16 and a beta of 1.18.
Bruker (NASDAQ:BRKR - Get Free Report) last announced its earnings results on Thursday, February 13th. The medical research company reported $0.76 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.75 by $0.01. Bruker had a net margin of 3.36% and a return on equity of 21.01%. Analysts anticipate that Bruker Co. will post 2.69 earnings per share for the current fiscal year.
Bruker Dividend Announcement
The business also recently declared a quarterly dividend, which was paid on Friday, March 28th. Investors of record on Monday, March 17th were issued a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.55%. The ex-dividend date was Monday, March 17th. Bruker's dividend payout ratio is currently 26.32%.
Analysts Set New Price Targets
A number of brokerages have recently commented on BRKR. The Goldman Sachs Group raised Bruker from a "sell" rating to a "neutral" rating and set a $60.00 price objective for the company in a research report on Thursday, December 5th. Bank of America increased their price objective on shares of Bruker from $78.00 to $80.00 and gave the company a "buy" rating in a research report on Friday, December 13th. UBS Group began coverage on shares of Bruker in a research report on Tuesday, December 10th. They set a "neutral" rating and a $66.00 price objective for the company. Stifel Nicolaus dropped their target price on Bruker from $70.00 to $57.00 and set a "hold" rating on the stock in a report on Friday, February 14th. Finally, Barclays decreased their price target on Bruker from $69.00 to $65.00 and set an "overweight" rating for the company in a report on Monday, February 10th. Six investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, Bruker has a consensus rating of "Moderate Buy" and an average price target of $70.50.
Get Our Latest Stock Analysis on Bruker
Bruker Profile
(
Free Report)
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.
Featured Articles
Before you consider Bruker, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bruker wasn't on the list.
While Bruker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
